Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 107

Similar articles for PubMed (Select 21682349)

1.

Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence.

Jarosławski S, Toumi M.

Appl Health Econ Health Policy. 2011 Jul 1;9(4):209-15. doi: 10.2165/11592960-000000000-00000.

PMID:
21682349
2.

Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Towse A.

Br J Clin Pharmacol. 2010 Sep;70(3):360-6. doi: 10.1111/j.1365-2125.2010.03740.x.

3.

Procedures and methods of benefit assessments for medicines in Germany.

Bekkering GE, Kleijnen J.

Eur J Health Econ. 2008 Nov;9 Suppl 1:5-29. doi: 10.1007/s10198-008-0122-5.

PMID:
18987905
4.

Comparing patient access to pharmaceuticals in the UK and US.

Cohen J, Cairns C, Paquette C, Faden L.

Appl Health Econ Health Policy. 2006;5(3):177-87.

PMID:
17132032
5.
6.

[Procedures and methods of benefit assessments for medicines in Germany].

Bekkering GE, Kleijnen J.

Dtsch Med Wochenschr. 2008 Dec;133 Suppl 7:S225-46. doi: 10.1055/s-0028-1100954. Epub 2008 Nov 25. German.

PMID:
19034813
7.

Future drug prices and cost-effectiveness analyses.

Hoyle M.

Pharmacoeconomics. 2008;26(7):589-602.

PMID:
18563950
8.

[Risk sharing methods in middle income countries].

Inotai A, Kaló Z.

Acta Pharm Hung. 2012;82(1):43-52. Review. Hungarian.

PMID:
22570986
9.
10.

An assessment of the impact of the NHS Health Technology Assessment Programme.

Hanney S, Buxton M, Green C, Coulson D, Raftery J.

Health Technol Assess. 2007 Dec;11(53):iii-iv, ix-xi, 1-180. Review.

11.

Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.

Jarosławski S, Toumi M.

BMC Health Serv Res. 2011 Oct 8;11:259. doi: 10.1186/1472-6963-11-259. Review.

12.

Clinical effectiveness and cost-effectiveness of drotrecogin alfa (activated) (Xigris) for the treatment of severe sepsis in adults: a systematic review and economic evaluation.

Green C, Dinnes J, Takeda A, Shepherd J, Hartwell D, Cave C, Payne E, Cuthbertson BH.

Health Technol Assess. 2005 Mar;9(11):1-126, iii-iv.

13.
14.

The UK pharmaceutical market. An overview.

Towse A.

Pharmacoeconomics. 1996;10 Suppl 2:14-25.

PMID:
10163432
15.

A comparative analysis of two contrasting European approaches for rewarding the value added by drugs for cancer: England versus France.

Drummond M, de Pouvourville G, Jones E, Haig J, Saba G, Cawston H.

Pharmacoeconomics. 2014 May;32(5):509-20. doi: 10.1007/s40273-014-0144-z.

PMID:
24599784
16.

Comparison of anticancer drug coverage decisions in the United States and United Kingdom: does the evidence support the rhetoric?

Mason A, Drummond M, Ramsey S, Campbell J, Raisch D.

J Clin Oncol. 2010 Jul 10;28(20):3234-8. doi: 10.1200/JCO.2009.26.2758. Epub 2010 May 24.

17.

Straight talk with... Mark Sculpher. Interview by Kate Ravilious.

Sculpher M.

Nat Med. 2012 Sep;18(9):1315. doi: 10.1038/nm0912-1315.

PMID:
22961148
18.

Economic evaluation and decision making in the UK.

Buxton MJ.

Pharmacoeconomics. 2006;24(11):1133-42. Review.

PMID:
17067197
19.

The role of NICE technology appraisal in NHS rationing.

Walker S, Palmer S, Sculpher M.

Br Med Bull. 2007;81-82:51-64. Epub 2007 Apr 4. Review.

PMID:
17409119
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk